Market revenue in 2022 | USD 144.9 million |
Market revenue in 2030 | USD 312.7 million |
Growth rate | 10.1% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 51.69% in 2022. Horizon Databook has segmented the France non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
The market in this country is expected to grow at a lucrative rate during the forecast period owing to an increase in the prevalence of Down syndrome, government support, and consumer awareness. In France, unlike other genetic tests for children and adults, NIPT is broadly performed and prescribed in private practices, leading to coverage by private and public insurance systems.
Key market players in the region are continuously undertaking efforts to increase their market shares by developing novel products by focusing on two areas of improvement- detecting a greater number of anomalies and limiting analysis failures. Such initiatives are expected to fuel market growth over the forecast period.
In addition, rising number of strategic initiatives by key players and approvals for NIPTs are positively impacting the market in France. For instance, in March 2020, Yourgene. AGX-DPNI is a newly formed entity that sells cytogenetic and pharmaceutical laboratory products.
Horizon Databook provides a detailed overview of country-level data and insights on the France non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into France non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account